

Gen 1632
#9
LSS
3/4/00

FULBRIGHT & JAWORSKI L.L.P

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/418-3000
FACSIMILE: 512/474-7577

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/418-3184

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG



MAR 03 2000

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
2/22/00 Date	 Steven L. Highlander

February 22, 2000

FILE: UTSD:548

Assistant Commissioner for Patents
Washington, DC 20231

RE: SN 09/061,417 "METHODS AND COMPOSITIONS FOR THERAPEUTIC INTERVENTION IN CARDIAN HYPERTROPHY" – Eric N. Olson et al.
(UTSMC/DAL:548)

Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, references (B1, and C59-C64), and a copy of the PCT Search Report.

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/UTSD:548/HYL.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.


Assistant Commissioner for Patents

February 22, 2000

Page 2

Please forward any reply to this communication directly to our Austin office for docketing purposes. The mailing address is 600 Congress Avenue, Suite 2400, Austin, Texas 78701, and the Austin fax number is 512.474.7577.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'SH', is written over the printed name of Steven L. Highlander.

Steven L. Highlander

Reg. No. 37,642

HYL:rrb


Encl: As noted




CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

2/22/00
Date


Steven L. Highlander


ZDS
3/4/00

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Eric N. Olson et al.

Serial No.: 09/061,417

Filed: 04/16/1998

For: METHODS AND COMPOSITIONS FOR
THERAPEUTIC INTERVENTION IN
CARDIAC HYPERTROPHY

Group Art Unit: 1632

Examiner: Anne-Marie Baker, Ph.D.

Atty. Dkt. No.: UTSD:548/HYL

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

MAR 03 2000

TECH CENTER 1600/2900

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/UTSD:548/HYL.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicants hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application. A copy of the search report is enclosed.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI LLP
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 418-3000

Date:

2/22/00